Cantor Fitzgerald Reiterates Overweight on Artiva Biotherapeutics, Maintains $40 Price Target

Cantor Fitzgerald analyst Josh Schimmer has reiterated an Overweight rating on Artiva Biotherapeutics (NASDAQ: ARTV) and maintained a price target of $40 for the company's stock. No specific financial figures or strategic changes were mentioned in the article.